1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2022 Report . Accessed August 15, 2022. https://goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf
2. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19:10. doi:10.1186/s12931-017-0710-y
3. Haidl P, Heindl S, Siemon K, et al. Inhalation device requirements for patients’ inhalation maneuvers. Respir Med . 2016;118:65-75. doi: 10.1016/j.rmed.2016.07.013
4. van Geffen WH, Douma WR, Slebos DJ, et al. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database Syst Rev . 2016;2016:CD011826. doi:10.1002/14651858.CD011826.pub2
5. Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv . 2017;30:381-387. doi:10.1089/jamp.2017.1416
6. Iwanaga T, Tohda Y, Nakamura S, et al. The Respimat soft mist inhaler: implications of drug delivery characteristics for patients. Clin Drug Investig. 2019;39:1021-1030. doi:10.1007/s40261-019-00835-z
7. Navaie M, Dembek C, Cho-Reyes S, et al. Device use errors with soft mist inhalers: a global systematic literature review and meta-analysis. Chron Respir Dis . 2020;17:1479973119901234. doi:10.1177/1479973119901234
8. Sharma G, Mahler DA, Mayorga VM, et al. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr Pulm Dis. 2017;4:217-224. doi: 10.15326/jcopdf.4.3.2017.0183
9. Chen SY, Huang CK, Peng HC, et al. Peak-inspiratory-flow-rate guided inhalation therapy reduce severe exacerbation of COPD. Front Pharmacol. 2021;12:704316. doi: 10.3389/fphar.2021.704316
10. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med . 2011;105:930-938. doi:10.1016/j.rmed.2011.01.005
11. Fathima M, Bawa Z, Mitchell B, et al. COPD management in community pharmacy results in improved inhaler use, immunization rate, COPD action plan ownership, COPD knowledge, and reductions in exacerbation rates. Int J Chron Obstruct Pulmon Dis. 2021;16:519-533. doi: 10.2147/COPD.S288792
12. van der Molen T, van Boven JF, Maguire T, et al. Optimizing identification and management of COPD patients – reviewing the role of the community pharmacist. Br J Clin Pharmacol. 2017;83:192-201. doi: 10.1111/bcp.13087
13. Brunetti L, Poiani G, Dhanaliwala F, et al. Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma. Am J Health Syst Pharm . 2015;72:1026-1035. doi:10.2146/ajhp140551
14. Brown CD, McCrory DC, White J. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2001;2001:CD002984. doi: 10.1002/14651858.CD002984
15. Kew KM, Mavergames C, Walters JAE. Long-acting beta2 -agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(10):CD010177. doi: 10.1002/14651858.CD010177.pub2
16. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev . 2014;2014:CD009285. doi:10.1002/14651858.CD009285.pub3
17. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev . 2012;2012:CD009157. doi:10.1002/14651858.CD009157.pub2
18. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta2 -agonist in one inhaler versus long-acting beta2 -agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;2012:CD006829. doi: 10.1002/14651858.CD006829.pub2
19. Yun JH, Lamb A, Chase R, et al; COPDGene and ECLIPSE Investigators . Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141:2037-2047.e10. doi:10.1016/j.jaci.2018.04.010
20. Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J. 2018;52:1801219. doi:10.1183/13993003.01219-2018
21. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev . 2014:CD010115. doi: 10.1002/14651858.CD010115.pub2
22. Calverley PMA, Anderson JA, Celli B, et al; TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med . 2007;356:775-789. doi:10.1056/NEJMoa063070
23. Vestbo J, Anderson JA, Brook RD, et al; SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet . 2016;387:1817-1826. doi:10.1016/S0140-6736(16)30069-1
24. Farne HA, Cates CJ. Long-acting beta2 -agonist in addition to tiotropium versus either tiotropium or long-acting beta2 -agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015:CD008989. doi:10.1002/14651858.CD008989.pub3
25. Horita N, Goto A, Shibata Y, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017;2:CD012066. doi:10.1002/14651858.CD012066.pub2
26. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 208;391:1076-1084. doi:10.1016/S0140-6736(18)30206-X
27. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet . 2017;389:1919-1929. doi: 10.1016/S0140-6736(17)30188-5
28. Rabe KF, Martinez FJ, Ferguson GT, et al; ETHOS Investigators. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35-48. doi:10.1056/NEJMoa1916046
29. Rojas-Reyes MX, García Morales OM, Dennis RJ, et al. Combination inhaled steroid and long-acting beta2 -agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 20162016:CD008532. doi: 10.1002/14651858.CD008532.pub3
30. Sonnex K, Alleemudder H, Knaggs R. Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review. BMJ Open . 2020;10:e037509. doi:10.1136/bmjopen-2020-037509
31. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166:675-679. doi:10.1164/rccm.2112096
32. Au DH, Bryson CL, Chien JW, et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J Gen Intern Med. 2009;24:457-463. doi:10.1007/s11606-009-0907-y
33. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med . 2005;142:233-239. doi: 10.7326/0003-4819-142-4-200502150-00005